Published in J Cell Biochem on March 01, 2012
Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris. PLoS One (2013) 1.09
Comparative Genomics of X-linked Muscular Dystrophies: The Golden Retriever Model. Curr Genomics (2013) 0.90
Histone Deacetylases in Bone Development and Skeletal Disorders. Physiol Rev (2015) 0.87
MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma. Oncotarget (2016) 0.80
Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma. Sci Rep (2015) 0.78
The Association of Endothelin-1 Signaling with Bone Alkaline Phosphatase Expression and Protumorigenic Activities in Canine Osteosarcoma. J Vet Intern Med (2015) 0.75
The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol (2007) 16.46
On respiratory impairment in cancer cells. Science (1956) 14.07
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 10.73
Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13
Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res (2008) 3.58
A systems approach to mapping DNA damage response pathways. Science (2006) 3.55
The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med (1986) 3.27
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol (2008) 3.12
Clinical studies of histone deacetylase inhibitors. Clin Cancer Res (2009) 2.68
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer (2008) 2.67
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 2.40
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol (2007) 2.39
Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res (2008) 2.36
Molecular pathogenesis of osteosarcoma. DNA Cell Biol (2007) 2.31
Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. EMBO J (2001) 2.30
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol (2010) 2.17
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene (2002) 2.02
Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem (2004) 1.91
Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res (2005) 1.65
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res (2007) 1.62
Comparative biology of human and canine osteosarcoma. Anticancer Res (2007) 1.60
Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J Biol Chem (2000) 1.55
Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res (2005) 1.51
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem (2004) 1.43
Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther (2010) 1.37
Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas (2008) 1.33
Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology (2007) 1.33
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell (2009) 1.33
Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-kappaB in human osteosarcoma. Clin Sci (Lond) (2006) 1.32
Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother (2006) 1.30
Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol (1983) 1.27
Endothelin-1: a multifunctional molecule in cancer. Br J Cancer (2003) 1.23
Role of oxidative phosphorylation in Bax toxicity. Mol Cell Biol (2000) 1.20
Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs (1990) 1.14
A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics (2008) 1.14
Network responses to DNA damaging agents. DNA Repair (Amst) (2004) 1.05
Systems biology approach to identification of biomarkers for metastatic progression in cancer. BMC Bioinformatics (2008) 1.04
The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol (2010) 0.99
Histone deacetylases in control of skeletogenesis. J Cell Biochem (2007) 0.96
Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer (2009) 0.95
Tissue-dependent and -independent gene expression changes in metastatic colon cancer. Oncol Rep (2008) 0.92
Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma. Gene (2006) 0.92
Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors. BMC Genomics (2007) 0.91
Induction of apoptosis in human osteosarcoma Saos-2 cells by the proteasome inhibitor MG132 and the protective effect of pRb. Cell Death Differ (2003) 0.88
Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother (2006) 0.85
Effects of secreted frizzled-related protein 3 on osteoblasts in vitro. J Bone Miner Res (2004) 0.85
Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132. Cell Biol Int (2007) 0.83
Transcriptional repression of E2F gene by proteasome inhibitors in human osteosarcoma cells. Biochem Biophys Res Commun (2004) 0.83
Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo. J Pharmacol Exp Ther (2003) 0.79
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A (2010) 8.05
Characterization of peripheral circadian clocks in adipose tissues. Diabetes (2006) 3.06
Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med (2002) 1.49
Autophagy and cancer therapy. Mol Pharmacol (2014) 1.38
Yield and characterization of subcutaneous human adipose-derived stem cells by flow cytometric and adipogenic mRNA analyzes. Cytotherapy (2010) 1.32
Circadian oscillation of gene expression in murine calvarial bone. J Bone Miner Res (2007) 1.20
IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem (2004) 1.15
GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res (2008) 1.10
Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clin Cancer Res (2009) 1.06
Genomic instability and telomere fusion of canine osteosarcoma cells. PLoS One (2012) 1.05
Systems biology approach to identification of biomarkers for metastatic progression in cancer. BMC Bioinformatics (2008) 1.04
Expression profiling in canine osteosarcoma: identification of biomarkers and pathways associated with outcome. BMC Cancer (2010) 1.02
Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med (2005) 1.00
The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol (2010) 0.99
An asymmetric synthesis of 1,2,4-trioxane anticancer agents via desymmetrization of peroxyquinols through a Brønsted acid catalysis cascade. J Am Chem Soc (2012) 0.98
Tuning the magnetic resonance imaging properties of positive contrast agent nanoparticles by surface modification with RAFT polymers. Langmuir (2009) 0.98
Prospective influences of circadian clocks in adipose tissue and metabolism. Nat Rev Endocrinol (2010) 0.97
Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med (2007) 0.93
Polymer-modified gadolinium metal-organic framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and treatment of cancer. Biomacromolecules (2009) 0.92
Expression and function of survivin in canine osteosarcoma. Cancer Res (2011) 0.90
Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985-1995). J Am Vet Med Assoc (2003) 0.89
Maternal and fetal response to fetal persistent infection with bovine viral diarrhea virus. Am J Reprod Immunol (2010) 0.89
Persistent fetal infection with bovine viral diarrhea virus differentially affects maternal blood cell signal transduction pathways. Physiol Genomics (2008) 0.89
Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. Clin Exp Metastasis (2011) 0.88
Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses. Cancer Immunol Immunother (2009) 0.88
c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis (2003) 0.87
Circadian rhythms in adipose tissue: an update. Curr Opin Clin Nutr Metab Care (2011) 0.87
HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors. BMC Vet Res (2013) 0.85
An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis. Clin Exp Metastasis (2010) 0.85
Proteome of human subcutaneous adipose tissue stromal vascular fraction cells versus mature adipocytes based on DIGE. J Proteome Res (2011) 0.85
Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J Vet Intern Med (2002) 0.83
Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. J Vet Intern Med (2007) 0.83
Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. Clin Cancer Res (2010) 0.82
Plasma synthesis of carbon magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery. J Biomater Sci Polym Ed (2004) 0.81
Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol (2004) 0.81
Regional societies: fostering competitive research through virtual infrastructures. PLoS Biol (2004) 0.80
Immunohistochemical characterization of feline oral squamous cell carcinoma. Am J Vet Res (2012) 0.80
Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). J Am Vet Med Assoc (2006) 0.78
Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere. Cancer Chemother Pharmacol (2015) 0.78
Optofluidic intracavity spectroscopy of canine hemangiosarcoma. IEEE Trans Biomed Eng (2010) 0.77
Biological aging alters circadian mechanisms in murine adipose tissue depots. Age (Dordr) (2012) 0.77
Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Vet Res (2008) 0.76
The immunosignature of canine lymphoma: characterization and diagnostic application. BMC Cancer (2014) 0.76
SAHA and hemangiosarcoma: another view. Vet Comp Oncol (2005) 0.75
Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor. BMC Vet Res (2014) 0.75
Multiple distinct malignancies in dogs: 53 cases. J Am Anim Hosp Assoc (2010) 0.75
What Is Your Diagnosis? Renal adenocarcinoma. J Am Vet Med Assoc (2015) 0.75
Malignant mesenchymoma with widespread metastasis including bone marrow involvement in a dog. Vet Clin Pathol (2014) 0.75
What is your diagnosis? Extraskeletal osteosarcoma. J Am Vet Med Assoc (2012) 0.75
Cytotoxic chemotherapy: new players, new tactics. J Am Anim Hosp Assoc (2005) 0.75
Diagnosis and management of lymphoma in a green iguana (Iguana iguana). J Am Vet Med Assoc (2011) 0.75
Successful treatment of acute tumor lysis syndrome in a dog with multicentric lymphoma. J Vet Intern Med (2008) 0.75
Tyrosine kinase inhibitor special issue. Vet Comp Oncol (2012) 0.75
Comparison of fluid types for resuscitation after acute blood loss in mallard ducks (Anas platyrhynchos). J Vet Emerg Crit Care (San Antonio) (2009) 0.75